From: Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria
 | Unadjusted model HR (96% CI) | P-Value | Adjusted model HR (95% CI) | P-Value |
---|---|---|---|---|
Gender | ||||
 Male(referent) |  | 0.46 |  |  |
 Female | 1.49 (0.51–4.39) |  |  |  |
Age(years) | ||||
  ≤ 40(referent) |  |  |  | 0.16 |
  > 40 | 5.12 (1.45–18.08) | 0.01 | 1.04 (0.98–1.10) |  |
Histologic subtype | ||||
 HL(referent) |  | 0.99 |  |  |
 NHL | 1.01 (0.23–4.52) |  |  |  |
Stage | ||||
 I & II(referent) |  | 0.001 |  | 0.03 |
 III & IV | 11.33 (2.55–50.26) |  | 5.45 (1.14–26.06) |  |
Chemotherapy cycles | ||||
  > 4(referent) |  | 0.004 |  | 0.21 |
  ≤ 4 | 6.43 (1.80–22.89) |  | 2.40 (0.61–9.25) |  |
Comorbidity | ||||
 Absent(referent) |  | 0.03 |  |  |
 Present | 3.43 (1.10–10.78) |  |  |  |
HIV serostatus | ||||
 Negative(referent) |  | 0.04 |  | 0.56 |
 Positive | 3.32 (1.05–10.51) |  | 1.49 (0.42–5.01) |  |